Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Trial updates in myeloma: COLUMBA and POLLUX

Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, highlights some of the recent study updates in myeloma including a body-weight subgroup analysis of the COLUMBA study (NCT03277105) which compared subcutaneous (SC) vs intravenous daratumumab in patients with relapsed/refractory multiple myeloma. The analysis concluded that higher SC daratumumab concentrations in patients ≤65 kg had no clinically relevant effect on safety suggesting no weight-based dose individualization is needed. Dr Jenner also discussed data coming from the POLLUX (NCT02076009) study which compared daratumumab, lenalidomide and dexamethasone with lenalidomide and dexamethasone. A significant progression-free survival was observed with the patients taking the daratumumab-containing regimen. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).